(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.05%) $0.926
(-0.06%) $10.83
(-0.09%) $0.792
(-0.09%) $92.49
-0.79% DKK 881.30
Live Chart Being Loaded With Signals
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease...
Stats | |
---|---|
Today's Volume | 2.45M |
Average Volume | 2.73M |
Market Cap | 3 966.08B |
EPS | DKK0 ( 2024-01-30 ) |
Next earnings date | ( DKK5.38 ) 2024-05-01 |
Last Dividend | DKK0 ( N/A ) |
Next Dividend | DKK0 ( N/A ) |
P/E | 47.33 |
ATR14 | DKK0.656 (0.07%) |
Volume Correlation
Novo Nordisk A/S Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Novo Nordisk A/S Correlation - Currency/Commodity
Novo Nordisk A/S Financials
Annual | 2023 |
Revenue: | DKK232.26B |
Gross Profit: | DKK196.50B (84.60 %) |
EPS: | DKK18.67 |
Q4 | 2023 |
Revenue: | DKK65.86B |
Gross Profit: | DKK55.85B (84.80 %) |
EPS: | DKK4.92 |
Q3 | 2023 |
Revenue: | DKK58.73B |
Gross Profit: | DKK49.02B (83.46 %) |
EPS: | DKK5.02 |
Q2 | 2023 |
Revenue: | DKK54.30B |
Gross Profit: | DKK46.44B (85.53 %) |
EPS: | DKK8.65 |
Financial Reports:
No articles found.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators